ENCell이엔셀

ENCell's shares have fallen sharply and the company is still deeply loss-making, though it has won a new CAR-T processing designation.

ENCell is a Korean cell and gene therapy developer and CDMO that listed on KOSDAQ in August 2024. Over the trailing twelve months to H1 2026 it reported revenue of about ₩4.2B against an operating loss of about ₩18.2B, and free cash flow was negative about ₩13.6B. The share price closed at ₩4,590 on 2026-10-27, down 64.2% over one year, near its 52-week low of ₩4,585.

What stands out

• Revenue fell from about ₩7.2B in 2024 to about ₩5.3B in 2025 and to about ₩4.2B on a trailing basis, while operating losses stayed around ₩16B to ₩18B a year.
• Trailing operating margin is -437.3% and net margin is -471.2%, so the business is not yet covering its costs.
• Cash of about ₩21.4B is more than borrowings of about ₩9.8B, but liabilities are 97.7% of equity and the free cash flow deficit is large.
• The data shows no dividend and no usable price-to-earnings figure because earnings are negative; price-to-book is 1.8 and price-to-sales is 12.2.
• The latest headline reports ENCell being designated as a commercial cell processing center for CAR-T by a global pharma company, but the data does not give contract size or timing.
• Foreign ownership fell from 4.5% to 2.5% over about 60 days, and the one-year fair value model gives a base value of ₩654 per share, well below the current price; the data does not explain the basis for these figures beyond the stated method.

What to watch

• Next periodic results and whether revenue growth returns, since the data shows declining sales for two years.
• Further filings on the conversion price adjustment for the 1st series instruments and the major management matter, which could affect dilution and governance.
• Financing needs given the negative free cash flow and the reliance on borrowings; the data does not show a funding plan.